Literature DB >> 2969508

Binding of toremifene to human serum proteins.

H Sipilä1, V Näntö, L Kangas, M Anttila, T Halme.   

Abstract

The in vitro protein binding of toremifene in human serum was measured by ultracentrifugation using 3H-toremifene together with unlabeled toremifene, 50, 500, and 5000 ng/ml. Of the total radioactivity 99.7 per cent was bound to the proteins independent of the concentration of the unlabeled drug. Binding of toremifene to different protein fractions was studied by adding 3H-toremifene and 500 ng/ml of cold toremifene to normal serum. The serum samples were exposed to agarose gel electrophoresis to fractionate different proteins. The radioactivity was localized using a position-sensitive proportional counter. After that the proteins were visualized by staining. Of the total protein bound radioactivity 92 per cent was bound to albumin, about 6 per cent to beta 1 globulin fraction and about 2 per cent to a fraction between albumin and alpha 1 globulins, part of this probably to alpha 1 acid glycoprotein.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2969508     DOI: 10.1111/j.1600-0773.1988.tb00911.x

Source DB:  PubMed          Journal:  Pharmacol Toxicol        ISSN: 0901-9928


  7 in total

Review 1.  Clinical pharmacokinetics of endocrine agents used in advanced breast cancer.

Authors:  P E Lønning; E A Lien; S Lundgren; S Kvinnsland
Journal:  Clin Pharmacokinet       Date:  1992-05       Impact factor: 6.447

Review 2.  Clinical pharmacokinetics of toremifene.

Authors:  T L Taras; G T Wurz; G R Linares; M W DeGregorio
Journal:  Clin Pharmacokinet       Date:  2000-11       Impact factor: 6.447

Review 3.  Toremifene. A review of its pharmacological properties and clinical efficacy in the management of advanced breast cancer.

Authors:  L R Wiseman; K L Goa
Journal:  Drugs       Date:  1997-07       Impact factor: 9.546

Review 4.  Pharmacokinetics of selective estrogen receptor modulators.

Authors:  Karla C Morello; Gregory T Wurz; Michael W DeGregorio
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

5.  Phase I clinical and pharmacokinetics study of high-dose toremifene in postmenopausal patients with advanced breast cancer.

Authors:  J Bishop; R Murray; L Webster; P Pitt; K Stokes; A Fennessy; I Olver; G Leber
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

6.  Targeting chemosensitizing doses of toremifene based on protein binding.

Authors:  G T Wurz; V D Emshoff; M W DeGregorio; V J Wiebe
Journal:  Cancer Chemother Pharmacol       Date:  1993       Impact factor: 3.333

7.  Effect of toremifene on antipyrine elimination in the isolated perfused rat liver.

Authors:  L K Webster; A G Ellis; J F Bishop
Journal:  Cancer Chemother Pharmacol       Date:  1993       Impact factor: 3.333

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.